FDA approves first treatment for seizures in patients with rare form of genetic epilepsy

The FDA has approved Ztalmy for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder, or CDD, in patients aged 2 years and older, according to a press release from the manufacturer.
Ztalmy (ganaxolone; Marinus Pharmaceuticals Inc.) oral suspension is the first FDA-approved treatment specifically for seizures associated with CDD, a rare form of genetic epilepsy, the release said.
CDD is characterized by difficult-to-control seizures and severe neurodevelopmental impairment. It is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene,

The FDA has approved Ztalmy for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder, or CDD, in patients aged 2 years and older, according to a press release from the manufacturer.
Ztalmy (ganaxolone; Marinus Pharmaceuticals Inc.) oral suspension is the first FDA-approved treatment specifically for seizures associated with CDD, a rare form of genetic epilepsy, the release said.
CDD is characterized by difficult-to-control seizures and severe neurodevelopmental impairment. It is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene,